Treatment options for primary sclerosing cholangitis

Emmanouil Sinakos, Keith Lindor

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Primary sclerosing cholangitis is a cholestatic liver disease characterized by inflammation and fibrosis of intra-/extrahepatic bile ducts, leading to multifocal strictures. Primary sclerosing cholangitis exhibits a progressive course resulting in cirrhosis and the need for liver transplantation over a median period of 12 years. The disease is frequently associated with inflammatory bowel disease and carries an increased risk of colorectal cancer and cholangiocarcinoma. Despite extensive research, there is currently no effective medical treatment. Multiple drugs are shown to be ineffective in halting disease progression, including ursodeoxycholic acid, the most widely evaluated drug. High-dose ursodeoxycholic acid (28-30 mg/kg/day) was recently shown to increase the adverse events rate. Endoscopic or radiological dilatation of a 'dominant stricture may lead to symptomatic and biochemical improvement. However, liver transplantation is the only life-prolonging treatment for patients with end-stage disease. Studies with promising drugs, such as antibiotics, antifibrotic agents and bile acid derivatives, are eagerly awaited.

Original languageEnglish (US)
Pages (from-to)473-488
Number of pages16
JournalExpert Review of Gastroenterology and Hepatology
Volume4
Issue number4
DOIs
StatePublished - Aug 2010
Externally publishedYes

Fingerprint

Sclerosing Cholangitis
Ursodeoxycholic Acid
Liver Transplantation
Pathologic Constriction
Fibrosis
Pharmaceutical Preparations
Extrahepatic Bile Ducts
Cholangiocarcinoma
Bile Acids and Salts
Inflammatory Bowel Diseases
Disease Progression
Liver Diseases
Dilatation
Colorectal Neoplasms
Therapeutics
Anti-Bacterial Agents
Inflammation
Research

Keywords

  • cholangiocarcinoma
  • inflammatory bowel disease
  • liver transplantation
  • primary sclerosing cholangitis
  • ursodeoxycholic acid

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Treatment options for primary sclerosing cholangitis. / Sinakos, Emmanouil; Lindor, Keith.

In: Expert Review of Gastroenterology and Hepatology, Vol. 4, No. 4, 08.2010, p. 473-488.

Research output: Contribution to journalArticle

@article{d95abda0e43b4ca39c4163f03c9d0044,
title = "Treatment options for primary sclerosing cholangitis",
abstract = "Primary sclerosing cholangitis is a cholestatic liver disease characterized by inflammation and fibrosis of intra-/extrahepatic bile ducts, leading to multifocal strictures. Primary sclerosing cholangitis exhibits a progressive course resulting in cirrhosis and the need for liver transplantation over a median period of 12 years. The disease is frequently associated with inflammatory bowel disease and carries an increased risk of colorectal cancer and cholangiocarcinoma. Despite extensive research, there is currently no effective medical treatment. Multiple drugs are shown to be ineffective in halting disease progression, including ursodeoxycholic acid, the most widely evaluated drug. High-dose ursodeoxycholic acid (28-30 mg/kg/day) was recently shown to increase the adverse events rate. Endoscopic or radiological dilatation of a 'dominant stricture may lead to symptomatic and biochemical improvement. However, liver transplantation is the only life-prolonging treatment for patients with end-stage disease. Studies with promising drugs, such as antibiotics, antifibrotic agents and bile acid derivatives, are eagerly awaited.",
keywords = "cholangiocarcinoma, inflammatory bowel disease, liver transplantation, primary sclerosing cholangitis, ursodeoxycholic acid",
author = "Emmanouil Sinakos and Keith Lindor",
year = "2010",
month = "8",
doi = "10.1586/egh.10.33",
language = "English (US)",
volume = "4",
pages = "473--488",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Treatment options for primary sclerosing cholangitis

AU - Sinakos, Emmanouil

AU - Lindor, Keith

PY - 2010/8

Y1 - 2010/8

N2 - Primary sclerosing cholangitis is a cholestatic liver disease characterized by inflammation and fibrosis of intra-/extrahepatic bile ducts, leading to multifocal strictures. Primary sclerosing cholangitis exhibits a progressive course resulting in cirrhosis and the need for liver transplantation over a median period of 12 years. The disease is frequently associated with inflammatory bowel disease and carries an increased risk of colorectal cancer and cholangiocarcinoma. Despite extensive research, there is currently no effective medical treatment. Multiple drugs are shown to be ineffective in halting disease progression, including ursodeoxycholic acid, the most widely evaluated drug. High-dose ursodeoxycholic acid (28-30 mg/kg/day) was recently shown to increase the adverse events rate. Endoscopic or radiological dilatation of a 'dominant stricture may lead to symptomatic and biochemical improvement. However, liver transplantation is the only life-prolonging treatment for patients with end-stage disease. Studies with promising drugs, such as antibiotics, antifibrotic agents and bile acid derivatives, are eagerly awaited.

AB - Primary sclerosing cholangitis is a cholestatic liver disease characterized by inflammation and fibrosis of intra-/extrahepatic bile ducts, leading to multifocal strictures. Primary sclerosing cholangitis exhibits a progressive course resulting in cirrhosis and the need for liver transplantation over a median period of 12 years. The disease is frequently associated with inflammatory bowel disease and carries an increased risk of colorectal cancer and cholangiocarcinoma. Despite extensive research, there is currently no effective medical treatment. Multiple drugs are shown to be ineffective in halting disease progression, including ursodeoxycholic acid, the most widely evaluated drug. High-dose ursodeoxycholic acid (28-30 mg/kg/day) was recently shown to increase the adverse events rate. Endoscopic or radiological dilatation of a 'dominant stricture may lead to symptomatic and biochemical improvement. However, liver transplantation is the only life-prolonging treatment for patients with end-stage disease. Studies with promising drugs, such as antibiotics, antifibrotic agents and bile acid derivatives, are eagerly awaited.

KW - cholangiocarcinoma

KW - inflammatory bowel disease

KW - liver transplantation

KW - primary sclerosing cholangitis

KW - ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=77955255696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955255696&partnerID=8YFLogxK

U2 - 10.1586/egh.10.33

DO - 10.1586/egh.10.33

M3 - Article

C2 - 20678020

AN - SCOPUS:77955255696

VL - 4

SP - 473

EP - 488

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

IS - 4

ER -